- Tonix Pharmaceuticals Holding Corp TNXP agreed to acquire all of the assets of Healion Bio Inc (Healion), including its entire portfolio of next-generation antiviral technology assets.
- Healion's drug portfolio includes a class of broad-spectrum small-molecule oral antiviral drug candidates with a novel host-directed mechanism of action.
- Deal terms were not disclosed.
- Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals, which inhibit virus proteins and processes.
- Tonix's TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have potent activity in vitro against SARS-CoV-2.
- Tonix plans to develop the TNX-3900 series of molecules as oral antivirals, either as monotherapy or in combination with other antivirals.
- In December, Tonix Pharmaceuticals obtained an exclusive license from Curia Global Inc to develop three humanized murine monoclonal antibodies (mAbs) for the treatment or prophylaxis of SARS-CoV-2 infection.
- In August, the company initiated patient enrolment in Phase 2 PREVAIL study of TNX-102 SL for patients with Long COVID syndrome (Long COVID).
- After the first 50% of enrolled patients have completed the study, an interim analysis is expected in the first half of 2023.
- Price Action: TNXP shares are up 1.71% at $1.19 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.